David A. Siegel Heron Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 42,100 shares of HRTX stock, worth $115,354. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,100
Previous 39,000
7.95%
Holding current value
$115,354
Previous $66,000
75.76%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding HRTX
# of Institutions
168Shares Held
119MCall Options Held
151KPut Options Held
103K-
Rubric Capital Management LP New York, NY26.7MShares$73.2 Million2.52% of portfolio
-
Orbimed Advisors LLC San Diego, CA10.1MShares$27.7 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$22.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$20 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$19.1 Million21.7% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $325M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...